Eli Lilly (NYSE:LLY) has been making headlines recently with its weight-loss drug Zepbound (tirzepatide). Eli Lilly ...
One of Eli Lilly's potential competitors in the weight loss market just reported unimpressive trial results. The company ...
The trial enrolled 751 adults with obesity or overweight conditions and at least one weight-related medical problem ...
The U.K. will soon offer Eli Lilly's Mounjaro for people with obesity — but only to a small share of those medically eligible ...